Asthma exacerbation severity
Reading File
Finding Sources
Finding Sources
Searching PubMed
"asthma exacerbation" AND "severity classification"
Reading File
Reading File
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
I now have comprehensive data from multiple authoritative textbooks. Here is the full clinical overview:
Asthma Exacerbation Severity
Definition
An asthma exacerbation is a worsening of asthma characterized by increased shortness of breath, coughing, and/or chest tightness with objective airflow limitation (decreased peak flow or FEV1). Increased symptoms typically precede detectable decreases in airflow. The NIH task force defines an exacerbation as "a worsening of asthma requiring the use of systemic corticosteroids (or an increase in maintenance dose) to prevent a serious outcome."
Severity should be classified based on symptoms, signs, and objective measures of lung function.
Severity Classification (Adults)
Based on GINA and NAEPP guidelines, as presented in the Washington Manual and Murray & Nadel's Respiratory Medicine:
| Feature | Mild | Moderate | Severe | Impending Respiratory Arrest |
|---|---|---|---|---|
| FEV1 or PEF | >70% predicted/personal best | 40%-69% | <40% | <25% (or unable to measure) |
| Symptoms | Dyspnea on exertion | SOB with talking | SOB at rest | Severe SOB |
| Wheeze | Expiratory | Expiratory | Inspiratory + expiratory | May become absent (silent chest - ominous) |
| Accessory muscles | Minimal/none | Some use | Increased use + chest retraction | Paradoxical thoracoabdominal movement |
| Mental status | Normal | Normal | Agitation or confusion | Depressed mental status |
| RR | Normal | <28/min | >28/min | Same as severe |
| HR | Normal | <110 bpm | >110 bpm | May develop bradycardia |
| O2 sat (room air) | Normal | >91% | <91% | Respiratory depression possible |
| Pulsus paradoxus | Absent | Absent | >25 mmHg | Same as severe |
Data from the 2020 GINA Report and NAEPP Third Expert Panel - The Washington Manual of Medical Therapeutics, p. 325
Key Clinical Indicators of Severity
Accessory Muscle Use
- Subcostal and intercostal muscle use = mild to moderate obstruction
- Neck (scalene/suprasternal) muscle use = severe obstruction
- Absent/minimal air entry with a silent chest = severely compromised ventilation - insufficient airflow to generate wheezing; this is an ominous sign
Arterial Blood Gas (ABG) Interpretation
ABG is indicated in patients with severe distress or FEV1 <40% after initial treatment:
- Early/mild-moderate: PaCO2 is LOW (respiratory alkalosis) due to tachypnea and hyperventilation
- Prolonged/severe: PaCO2 normalizes or RISES due to severe obstruction, increased dead space, and respiratory muscle fatigue
- A normal or elevated PaCO2 in the absence of clinical improvement = impending respiratory failure - requires hospitalization and close monitoring
- PaO2 <60 mmHg = severe bronchoconstriction or complicating condition (PE, pneumonia, pulmonary edema)
ETCO2 Monitoring
Consider in all children with severe or life-threatening exacerbations. A rising ETCO2 is a marker of fatigue or disease worsening (expected PaCO2 is below normal in asthma due to increased minute ventilation).
Pediatric Scoring: PRAM (Pediatric Respiratory Assessment Measure)
Validated for ages 2-17 years:
| Parameter | 0 | 1 | 2 | 3 |
|---|---|---|---|---|
| Suprasternal retractions | Absent | - | Present | - |
| Scalene contraction | Absent | - | Present | - |
| Air entry | Normal | Decreased at bases | Widespread decrease | Absent/minimal |
| Wheezing | Absent | Expiratory only | Insp. + exp. | Audible without stethoscope / silent chest |
| SpO2 (room air) | ≥95% | 92%-94% | <92% | - |
- PRAM 0-3 = Mild
- PRAM 4-7 = Moderate
- PRAM 8-12 = Severe
- Impending respiratory failure is based on clinical presentation
A PRAM score ≥8 at 3 hours after ED presentation strongly predicts the need for admission. - Tintinalli's Emergency Medicine, p. 845
High-Risk Features for Asthma-Related Death
These patients warrant early ED evaluation and a lower threshold for admission:
- Previous near-fatal or intubated exacerbation
- Recent hospitalization or ED visit for asthma
- Overutilization of SABAs or underutilization of ICS
- Recent oral corticosteroid use
- Poor adherence to asthma action plans
- Comorbid psychiatric disease
ED Management by Severity
Mild-Moderate
- Albuterol 2-6 puffs via MDI+spacer OR 2.5 mg via nebulizer, repeated every 20 min
- Systemic corticosteroids promptly (prednisone 40-60 mg/day oral; oral is equivalent to IV at equivalent doses)
- SpO2 target >90%
- For mild-moderate disease with good self-management, quadrupling ICS is an alternative to oral corticosteroids
Severe
- Albuterol 2.5-5 mg q20min plus ipratropium 0.5 mg q20min via nebulizer - the combination reduces hospitalization rates at ED initiation
- Alternatively, continuous albuterol 10-15 mg over 1 hour with telemetry monitoring
- Systemic corticosteroids (methylprednisolone 1.5-2 mg/kg IV or oral equivalent)
- IV magnesium sulfate 2g over 20 min for severe exacerbations refractory to standard treatment - shown to improve lung function and reduce admission rates
- Heliox-driven albuterol nebulization (70:30 helium:oxygen) for severe exacerbations not responding to initial emergency treatment
Impending Respiratory Failure
- Low-level non-invasive positive pressure ventilation (without PEEP) for alert, cooperative patients not in immediate need of intubation
- Intubation is mandatory for respiratory arrest or impending arrest
- Ventilator strategy: permissive hypercapnia - low minute ventilation (RR 12-14/min, TV 6-8 mL/kg), high inspiratory flow rate, minimal/no PEEP to minimize dynamic hyperinflation
- Aggressive sedation; short-term paralysis if needed for patient-ventilator dyssynchrony
Discharge Criteria
- Patients failing to respond to albuterol within 30-60 min with persistent dyspnea and PEF <70% of baseline require hospital admission
- Discharged patients: prednisone 40 mg/day for 5-7 days plus initiation/increase of ICS
Sources:
- The Washington Manual of Medical Therapeutics, pp. 325, 330, 335-336
- Murray & Nadel's Textbook of Respiratory Medicine, pp. 1460-1461
- Tintinalli's Emergency Medicine, pp. 845-846
This is a shared conversation. Sign in to Orris to start your own chat.